324 related articles for article (PubMed ID: 29867997)
1. Tumor-Targeting Anti-CD20 Antibodies Mediate
Capuano C; Battella S; Pighi C; Franchitti L; Turriziani O; Morrone S; Santoni A; Galandrini R; Palmieri G
Front Immunol; 2018; 9():1031. PubMed ID: 29867997
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells Adapt to Cytomegalovirus Along a Functionally Static Phenotypic Spectrum in Human Immunodeficiency Virus Infection.
Holder KA; Lajoie J; Grant MD
Front Immunol; 2018; 9():2494. PubMed ID: 30483249
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
Bowles JA; Wang SY; Link BK; Allan B; Beuerlein G; Campbell MA; Marquis D; Ondek B; Wooldridge JE; Smith BJ; Breitmeyer JB; Weiner GJ
Blood; 2006 Oct; 108(8):2648-54. PubMed ID: 16825493
[TBL] [Abstract][Full Text] [Related]
4. NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection.
Schuch A; Zecher BF; Müller PA; Correia MP; Daul F; Rennert C; Tauber C; Schlitt K; Boettler T; Neumann-Haefelin C; Hengel H; Pircher H; Cerwenka A; Thimme R; Hofmann M
J Hepatol; 2019 Mar; 70(3):351-360. PubMed ID: 30342116
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus-Driven Adaption of Natural Killer Cells in NKG2C
Comeau EM; Holder KA; Fudge NJ; Grant MD
Viruses; 2019 Mar; 11(3):. PubMed ID: 30857329
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.
Capuano C; Romanelli M; Pighi C; Cimino G; Rago A; Molfetta R; Paolini R; Santoni A; Galandrini R
Cancer Res; 2015 Oct; 75(19):4097-108. PubMed ID: 26229120
[TBL] [Abstract][Full Text] [Related]
7. (Auto)Antibody Responses Shape Memory NK Cell Pool Size and Composition.
Capuano C; Pighi C; Battella S; Pulcinelli F; Santoro C; Ferretti A; Turriziani O; De Federicis D; Fionda C; Sciumè G; Galandrini R; Palmieri G
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327427
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.
Capuano C; Pighi C; Molfetta R; Paolini R; Battella S; Palmieri G; Giannini G; Belardinilli F; Santoni A; Galandrini R
Oncoimmunology; 2017; 6(3):e1290037. PubMed ID: 28405525
[TBL] [Abstract][Full Text] [Related]
9. NK cells generate memory-type responses to human cytomegalovirus-infected fibroblasts.
Newhook N; Fudge N; Grant M
Eur J Immunol; 2017 Jun; 47(6):1032-1039. PubMed ID: 28475279
[TBL] [Abstract][Full Text] [Related]
10. NKG2C(+)CD57(+) Natural Killer Cell Expansion Parallels Cytomegalovirus-Specific CD8(+) T Cell Evolution towards Senescence.
Heath J; Newhook N; Comeau E; Gallant M; Fudge N; Grant M
J Immunol Res; 2016; 2016():7470124. PubMed ID: 27314055
[TBL] [Abstract][Full Text] [Related]
11. CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ
Capuano C; Pighi C; Maggio R; Battella S; Morrone S; Palmieri G; Santoni A; Klein C; Galandrini R
Cancer Immunol Immunother; 2020 Apr; 69(4):501-512. PubMed ID: 31950225
[TBL] [Abstract][Full Text] [Related]
12. Human Adaptive Natural Killer Cells: Beyond NKG2C.
Wagner JA; Fehniger TA
Trends Immunol; 2016 Jun; 37(6):351-353. PubMed ID: 27179621
[TBL] [Abstract][Full Text] [Related]
13. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
Front Immunol; 2021; 12():641521. PubMed ID: 33796107
[TBL] [Abstract][Full Text] [Related]
14. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Rataj F; Jacobi SJ; Stoiber S; Asang F; Ogonek J; Tokarew N; Cadilha BL; van Puijenbroek E; Heise C; Duewell P; Endres S; Klein C; Kobold S
Br J Cancer; 2019 Jan; 120(1):79-87. PubMed ID: 30429531
[TBL] [Abstract][Full Text] [Related]
15. Late Development of FcεRγ
Muccio L; Falco M; Bertaina A; Locatelli F; Frassoni F; Sivori S; Moretta L; Moretta A; Della Chiesa M
Front Immunol; 2018; 9():1050. PubMed ID: 29868012
[TBL] [Abstract][Full Text] [Related]
16. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
17. Relationship of NKG2C Copy Number with the Distribution of Distinct Cytomegalovirus-Induced Adaptive NK Cell Subsets.
Muntasell A; Pupuleku A; Cisneros E; Vera A; Moraru M; Vilches C; López-Botet M
J Immunol; 2016 May; 196(9):3818-27. PubMed ID: 26994220
[TBL] [Abstract][Full Text] [Related]
18. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes.
Costa-García M; Ataya M; Moraru M; Vilches C; López-Botet M; Muntasell A
Front Immunol; 2019; 10():687. PubMed ID: 31001281
[TBL] [Abstract][Full Text] [Related]
19. IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion.
Rölle A; Pollmann J; Ewen EM; Le VT; Halenius A; Hengel H; Cerwenka A
J Clin Invest; 2014 Dec; 124(12):5305-16. PubMed ID: 25384219
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
